MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
PLx Pharma Retained Earnings 2011-2026 | PLXP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -148 M | -102 M | -86.9 M | -66.4 M | -67.3 M | -62.4 M | -41.1 M | -22.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.3 M | -148 M | -74.6 M |
Quarterly Retained Earnings PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -179 M | -171 M | -159 M | -148 M | -152 M | -130 M | -114 M | -102 M | -102 M | -102 M | -102 M | -86.9 M | -86.9 M | -86.9 M | -86.9 M | -66.4 M | -66.4 M | -66.4 M | -66.4 M | -67.3 M | -67.3 M | -67.3 M | -67.3 M | -52 M | -52 M | -52 M | -62.4 M | -41.1 M | -41.1 M | -41.1 M | -41.1 M | -22.3 M | -22.3 M | -22.3 M | -22.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -22.3 M | -179 M | -80.5 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.64 | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.05 | -2.34 % | $ 113 M |  Canada |
 |
Cronos Group
CRON
|
1.06 B | $ 2.59 | -0.77 % | $ 1.34 B | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.82 | -1.29 % | $ 53.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 10.75 | -2.54 % | $ 550 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
-609 M | $ 4.28 | -0.46 % | $ 265 M | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.69 | 7.78 % | $ 12 M |  China |
 |
Harrow Health
HROW
|
-134 M | $ 47.33 | -2.73 % | $ 1.54 B | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.29 | -1.91 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 21.5 | -1.08 % | $ 994 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.86 | -3.62 % | $ 2.14 B | Canada |
 |
Tilray
TLRY
|
-2.42 B | $ 7.49 | -1.77 % | $ 4.63 B | Canada |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.51 | 0.33 % | $ 3.37 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-182 M | $ 0.69 | -8.98 % | $ 2.98 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 14.37 | -1.61 % | $ 1.97 B | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 3.72 | -1.2 % | $ 490 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.38 | -1.89 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 1.01 | -7.34 % | $ 23.6 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 3.9 | -2.63 % | $ 117 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 12.07 | 0.96 % | $ 857 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.78 | -2.46 % | $ 3.45 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 6.15 | -3.98 % | $ 251 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.78 | -2.71 % | $ 37.3 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.26 | -1.74 % | $ 305 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.41 | -0.82 % | $ 25.2 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 15.89 | -1.48 % | $ 19.3 B | USA |